Save27%
Original price$ 21.95
Current price$ 15.95
SKU305732-451145
Get 24-hour relief from frequent heartburn with Nexium 24HR Tablets. It provides complete protection from frequent heartburn in easy-to-swallow tablets. Nexium 24HR tablets work by blocking acid directly at the source, giving you 24 hours of protection from frequent heartburn. Just one tablet a day provides all-day, all-night protection from frequent heartburn. Nexium 24HR is the #1 Selling OTC frequent heartburn brand.
Walgreens has agreed to plead guilty to importing unregistered pharmaceutical products and selling them for profit to the United States, under the importation provisions of the United States Patent Act.
The U. S. attorney for the Northern District of California said on Monday the criminal plea could result in a criminal fine ranging from $30,000 to $50,000, depending on how many packages there were, the maximum allowed under the Patent Act.
The maximum allowed under the Patent Act is two years of federal and state imprisonment, with a maximum fine of $100,000. The maximum allowed is two years and a fine of $250,000, or $10,000, whichever is less.
The government also said it was seeking to file a criminal complaint with the FDA regarding the marketing and sale of the products.
Under the terms of the plea agreement, the government will pay $30,000 in criminal fines and $50,000 in civil penalties, including civil costs.
The company would also pay $250,000 in criminal fines and $100,000 in civil penalties.
Federal prosecutors said they are pleased with the decision of the U. attorney to plead guilty to the criminal charges.
The company will continue to market its products under the brand name Nexium, according to the company's website.
“This agreement reflects our commitment to grow our business while continuing to provide our customers with the highest quality medications for the treatment of heart, lung, kidney, and other medical conditions,” said Brian Wilson, executive vice president and chief executive officer of the United States’ leading drug business, Nexium.
A Nexium patent expired in June, creating a generic version of the heart drug Nexium, used for the treatment of conditions including chest pain and chronic heartburn. It was later sold by Watson Pharmaceuticals, which was the maker of the generic.
The Food and Drug Administration has approved more than a dozen different Nexium products, including Nexium 1 mg and Nexium 40 mg tablets, to treat patients with different types of chronic heartburn, according to the FDA.
“These products are essential,” said Richard Follman, executive director of the FDA’s Office of Generic Drugs. “They are essential medicines for the treatment of heartburn. They have the same active ingredient that has been approved for the heartburn treatment of other people.”
Follman and his team of researchers at the University of Illinois-Chicago, said they have completed an analysis of the data to determine how many people were affected by heartburn.
The FDA has also been assessing the impact of Nexium and other prescription heartburn medications on the market, said Follman.
The FDA said it has received multiple reports of drug abuse in the United States, particularly in the form of marketing and sales of prescription drugs.
“This agreement provides the public with the information needed to determine whether a particular product is a good fit for a particular patient,” said Dr. Robert S. Gershenson, the FDA's senior vice president for product development. “We will continue to work with our partners to develop a strategy that provides the public with the information needed to determine if a particular product is suitable for a particular patient.”
Dr. Robert A. Hirsch, an assistant professor of medicine and associate director of the Division of Drug Products and Policy, said he and his team at the University of Illinois-Chicago had planned to market the products at various prices. “We’ve been working with the FDA to come up with an appropriate pricing plan and we’re pleased with the decision.”
The FDA has also been assessing the impact of Nexium, he said.
“We’re looking forward to working with our partners to provide the information needed to determine the best price for this specific product,” he said.
In addition to the potential for serious problems for patients, the company is also pursuing other possible risks and side effects associated with Nexium, including heartburn.
“Nexium is a prescription medication that can have a serious adverse reaction to heartburn, but it can also have a serious impact on a patient’s quality of life,” said John E. Bittman, an associate professor of medicine and director of the University of Chicago School of Medicine.
The FDA is also seeking to market a generic version of Nexium, he said.
“The FDA has already approved a generic version of Nexium, which is currently being marketed as a heartburn medication.
Pfizer said the US-based firm is in talks with the European Union over the rights of its generic drug,, after European officials said they are in talks over the issue.
The company's patent on Nexium (generic for "esomeprazole") is set to expire in the spring of 2019, and Pfizer's patent on Protonix (generic for "terbinafine") is set to expire in late 2017.
Pfizer said Pfizer is in talks with the European Union over the issue of the drug and that Pfizer "agreed to seek an agreement on this matter" after discussions about the patent.
"We are currently evaluating a number of potential terms and conditions to consider in the agreement," said Pfizer spokeswoman Christine Cramer.
The company said the European and US governments are "very close" to finalising their respective regulatory actions.
However, Pfizer said it was uncertain whether the US-based company will seek regulatory approval for the drug, and Pfizer had discussions with the European Union on the matter.
The US-based firm said the two sides were in discussions about the issue.
The European companies had been trying to reach agreement about the issue for some time.
Pfizer said in a statement that the US-based firm was "in discussions" regarding the matter.
The British firm said it was "incorporating discussions" with the EU.
Pfizer spokeswoman Emma Cox said the company "certainly" was in discussions with the EU.
The company has not disclosed how much of the cash it will receive will go toward research and development costs, although Pfizer said it has agreed to fund that project.
The European Union is in discussions with Pfizer, which will be deciding whether to seek the agreement.
The deal is set to take place in a two-week period, and is expected to be signed by Pfizer on Monday.
Pfizer said that while the US-based company will have a $2.7 billion annual net interest in the drug, it is "likely to continue its discussions with the EU and Pfizer".
The deal would see the company pay $10 billion to $12 billion to settle patent litigation, and pay $5 billion to $6 billion to fund a clinical trial.
The deal would be a significant step in Pfizer's attempt to get approval for its own generic versions of Nexium.
The US firm is expected to receive at least $3.5 billion in financing from the government and a second-quarter of $3.5 billion from the government.
Pfizer said its research and development budget, for a total of $13.3 billion, was $1.7 billion.
|PfizerCopyright by © 2025 pfizer. All rights reserved. No changes to this release.
Pfizer is a registered trademark of pfizer Inc.
This material may contain references to specific articles, not all of the time-and-a-half articles. All manner of material refers to specific articles, not to every other article.
Pfizer Inc is an international company, one of the world's leading pharmaceutical companies, and one of the world's leading research institutions and research institutions, offering a broad range of therapeutic products. We operate from more than 50 countries and have global operations across more than 40 countries.
We are committed to reporting on a wide range of important, high quality and innovative products and services. Please visit the for more information and to request a request.
Pfizer Inc is a registered trademark of pfizer Inc.
We are a company registered trademark of pfizer Inc. P& G Pharmaceuticals Inc and Pfizer Pharmaceuticals Inc, Inc have been registered trademarks in the United States of America and other countries. The brand name of a drug is the brand name of the drug used in a drug product. The brand name may be confusingly similar to a brand name brand brand. The brand name is a trade name of a company. In some cases a brand name may be a confusingly similar trade name to a brand name drug, or to any of a host of other brand names. The use of a ‘brand’ brand brand is not a way of saying that the product is the same as the original product.
Regular price₱10,000per package
Nexium (Esomeprazole) 30mg/5ml Oral Suspension is a proton pump inhibitor used to treat gastroesophageal reflux (GORD) and Zollinger-Ellison syndrome, two conditions that affect your stomach. It helps you to prevent this disorder from happening again. It is sold under the brand name Eslaw in capsule form and as a tablet in liquid form.
Nexium (Esomeprazole) 30mg/5ml Oral Suspension is a prescription medicine that helps your stomach by reducing acid production in the stomach and esophagus. The drug is sold under the brand name Eslaw in capsule form and a liquid form in the same package.$20 to $30 for 14 ml
Nexium is only indicated to treat the symptoms ofHelicobacter pylori infectionin people withHelicobacter pyloriand not to be taken by people withZollinger-Ellison syndrome.
Containssucroseto improve absorptionTake Nexium (Esomeprazole) as prescribed by your doctor. Follow the dosage instructions exactly. Take Nexiumwith foodor up2 hours beforefood intake. Do not change your doses or use Nexiummore than once a day
Active substanceEsomeprazole
Other:
Nexium is for external use only. Not suitable for baby or newborn infants.
Stade de France Pharmacy